Roche Holding, CH0012032048

Roche Holding stock rises 1.25 percent ahead of the open

Published on 09/23/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, Roche Holding stock stood at CHF 371.44 on SIX, 1.25 percent higher. The shares were CHF 4.36 below the 52-week high of CHF 375.80 as the enicepatide study update shaped trading.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor
Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock closed at CHF 371.44 on the SIX Swiss Exchange on September 22, 2026, up 1.25 percent. The shares finished CHF 4.36 below their 52-week high of CHF 375.80, a quantified comparison that placed the close near the top of the annual range.

September 22, 2026 in numbers

Roche Holding AG (ISIN CH0012032048, SIX: RO) traded between CHF 359.10 and CHF 371.44 during the September 22, 2026 session. The 52-week range was CHF 252.20 to CHF 375.80, while the market capitalization stood at CHF 344.458 billion as of September 21, 2026.

The session driver was the company update on enicepatide. As AD HOC NEWS reported on September 22, 2026, the 24 milligram dose produced mean weight loss of 15.5 percent after 48 weeks and reduced HbA1c by 2.65 percent in the Phase II study.

Today before the open

Roche enters the September 23, 2026 session with the clinical update as the latest company-specific trading reference. The next quarterly results are scheduled for February 4, 2027, according to finanzen.ch.

Disclaimer...

en | CH0012032048 | ROCHE HOLDING | boerse | 70163239 | bgmi